Corcept Therapeutics insider sale: 5,000 shares via Stifel on NASDAQ

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) Form 144 summary: This notice reports a proposed sale of 5,000 common shares through Stifel Nicolaus & Co. with an aggregate market value of $348,600.00. The shares were acquired the same day, 09/02/2025, by stock option exercise and payment was in cash. The filing lists the issuer's total shares outstanding as 105,370,000 and indicates the intended exchange as NASDAQ. The filer previously sold several blocks of common stock in June–August 2025, totaling multiple transactions reported in the filing.

Positive

• Disclosure compliance appears complete with broker, acquisition method, dates, and past transactions provided
• Transaction details specify acquisition by option exercise and payment in cash, reducing ambiguity about consideration

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine insider sale reporting; no new material disclosures beyond scheduled transactions and exercise details.

The Form 144 documents a planned market sale of 5,000 common shares by an insider following a stock option exercise on the same date, with payment in cash. The filing lists prior open-market dispositions by the same person in June–August 2025. This submission meets Rule 144 disclosure requirements by identifying broker, share counts, acquisition method, and intended exchange. There is no indication in the filing of undisclosed material information about the issuer or other governance changes.

Securities Analyst

TL;DR: Insider liquidity event of modest size relative to outstanding shares; likely low market impact.

The proposed sale of 5,000 shares at an aggregate market value of $348,600 is small relative to the reported 105,370,000 shares outstanding, suggesting limited dilution or market impact. The acquisition via option exercise on the sale date is disclosed, and multiple recent insider sales are listed, which investors may note for trading pattern context. The filing contains no earnings or operational metrics.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Co. Inc. 501 N. Broadway St Louis MO 63102	5000	348600.00	105370000	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Stock Option Exercise	Corcept Therapeutics Inc.			5000	09/02/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/01/2025	100	7350.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	06/02/2025	5000	390218.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/17/2025	3877	284864.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/18/2025	200	14680.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	08/01/2025	5823	393128.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What securities does the Form 144 for CORT report?

The filing reports a proposed sale of 5,000 common shares of Corcept Therapeutics (CORT).

When were the shares acquired and how were they acquired?

The shares were acquired on 09/02/2025 by stock option exercise and paid for in cash.

Who is the broker and which exchange is the sale intended for?

The broker is listed as Stifel Nicolaus & Co. Inc. and the intended exchange is NASDAQ.

What is the aggregate market value and shares outstanding reported?

Aggregate market value for the proposed sale is $348,600.00 and the filing lists 105,370,000 shares outstanding.

Has the filer sold shares recently?

Yes. The filing lists multiple recent sales by Joseph D. Lyon in June–August 2025, including transactions of 100, 5,000, 3,877, 200, and 5,823 shares.